Search Results for “” – Page 2 – OSLM

OSLM

Outcome Studies
in Laboratory Medicine

guest

👤

Learn more about this platform

Project:Cancer

Categories:Model

21 Publications found

The effect of PD-L1 testing on the cost-effectiveness and economic impact of immune checkpoint inhibitors for the second-line treatment of NSCLC.

b

Annals of oncology : official journal of the European Society for Medical Oncology

September 1, 2017

p Cancer

c Economics Highlighted Model
Cost-effectiveness of precision medicine in the fourth-line treatment of metastatic lung adenocarcinoma: An early decision analytic model of multiplex targeted sequencing.

b

Lung cancer (Amsterdam, Netherlands)

May 1, 2017

p Cancer

c Economics Model
A Cost-Effectiveness Analysis of Nivolumab versus Docetaxel for Advanced Nonsquamous NSCLC Including PD-L1 Testing.

b

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer

November 1, 2016

p Cancer

c Economics Model
Economic Evaluation of Companion Diagnostic Testing for EGFR Mutations and First-Line Targeted Therapy in Advanced Non-Small Cell Lung Cancer Patients in South Korea.

b

PloS one

January 1, 2016

p Cancer

c Economics Model
Cost-effectiveness analysis of EGFR mutation testing and gefitinib as first-line therapy for non-small cell lung cancer.

b

Lung cancer (Amsterdam, Netherlands)

October 1, 2015

p Cancer

c Economics Model
Bevacizumab, Pemetrexed, and Cisplatin, or Bevacizumab and Erlotinib for Patients With Advanced Non-Small-Cell Lung Cancer Stratified by Epidermal Growth Factor Receptor Mutation: Phase II Trial SAKK19/09.

b

Clinical lung cancer

September 1, 2015

p Cancer

c Economics Model
Outcome and economic implications of proteomic test-guided second- or third-line treatment for advanced non-small cell lung cancer: extended analysis of the PROSE trial.

b

Lung cancer (Amsterdam, Netherlands)

May 1, 2015

p Cancer

c Clinical outcomes Economics Model
Cost-effectiveness of multiplexed predictive biomarker screening in non-small-cell lung cancer.

b

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer

April 1, 2015

p Cancer

c Economics Model
A comparison of individualized treatment guided by VeriStrat with standard of care treatment strategies in patients receiving second-line treatment for advanced non-small cell lung cancer: A cost-utility analysis.

b

Lung cancer (Amsterdam, Netherlands)

December 1, 2013

p Cancer

c Clinical outcomes Economics Model
Gene-guided gefitinib switch maintenance therapy for patients with advanced EGFR mutation-positive non-small cell lung cancer: an economic analysis.

b

BMC cancer

January 29, 2013

p Cancer

c Economics Model